Front Street Capital Management Inc. Sells 71,928 Shares of Envista Holdings Co. (NYSE:NVST)

Front Street Capital Management Inc. decreased its holdings in Envista Holdings Co. (NYSE:NVST - Free Report) by 64.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,798 shares of the company's stock after selling 71,928 shares during the quarter. Front Street Capital Management Inc.'s holdings in Envista were worth $768,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of NVST. Venturi Wealth Management LLC lifted its holdings in shares of Envista by 528.4% in the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock worth $38,000 after acquiring an additional 1,638 shares during the last quarter. GAMMA Investing LLC boosted its position in Envista by 30.5% in the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock valued at $44,000 after buying an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Envista during the fourth quarter worth $53,000. Mitsubishi UFJ Trust & Banking Corp acquired a new position in shares of Envista during the fourth quarter worth $86,000. Finally, KBC Group NV lifted its stake in shares of Envista by 63.9% in the 4th quarter. KBC Group NV now owns 7,903 shares of the company's stock valued at $152,000 after acquiring an additional 3,082 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Jefferies Financial Group upped their target price on Envista from $20.00 to $22.00 and gave the stock a "hold" rating in a report on Thursday, January 23rd. UBS Group dropped their price objective on shares of Envista from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Monday, March 10th. Wells Fargo & Company set a $19.00 target price on shares of Envista in a report on Saturday, March 8th. Morgan Stanley set a $16.00 price target on shares of Envista in a research note on Tuesday, April 15th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Envista in a research report on Thursday, March 6th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Envista presently has a consensus rating of "Hold" and a consensus price target of $19.96.

Envista Stock Performance

NYSE:NVST traded up $0.75 on Wednesday, reaching $15.92. 1,637,462 shares of the company's stock were exchanged, compared to its average volume of 2,487,991. Envista Holdings Co. has a 52 week low of $14.22 and a 52 week high of $23.00. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -2.45, a P/E/G ratio of 1.27 and a beta of 1.12. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The stock has a fifty day simple moving average of $17.57 and a 200-day simple moving average of $19.16.

Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. As a group, sell-side analysts predict that Envista Holdings Co. will post 1 earnings per share for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.